{"id":728245,"date":"2023-02-02T09:10:26","date_gmt":"2023-02-02T14:10:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/"},"modified":"2023-02-02T09:10:26","modified_gmt":"2023-02-02T14:10:26","slug":"livanova-launches-sentiva-duo","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/","title":{"rendered":"LivaNova Launches SenTiva DUO"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\nLivaNova Launches SenTiva DUO\n<\/p>\n<p class=\"bwalignc\"><i>New device expands access to the latest technology <\/i><i>for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S.<\/i><\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nLivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO\u2122, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva\u2122, which is only available in a single-pin format. Now, with SenTiva DUO, patients considered \u201cthe pioneers of VNS Therapy\u201d who were originally implanted with a dual-pin lead and IPG can receive the benefits of the latest VNS Therapy technology.\n<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 449px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg\" alt=\"LivaNova's SenTiva DUO\u2122, an implantable pulse generator with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. (Photo: Business Wire)\" \/><\/p>\n<p style=\"font-size:85%\">LivaNova&#8217;s SenTiva DUO\u2122, an implantable pulse generator with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. (Photo: Business Wire)<\/p>\n<\/div>\n<p>\n\u201cThis new offering enables those VNS Therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva DUO, delivering the most advanced VNS Therapy treatment without the need for lead revision,\u201d said Dr. James Wheless, Professor and Chief, Pediatric Neurology, Le Bonheur Children\u2019s Hospital in Memphis, Tennessee. \u201cHaving access to SenTiva DUO offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment.\u201d\n<\/p>\n<p>\nSenTiva DUO offers the same therapeutic benefits as SenTiva. Both provide stimulation in response to rapid heart rate increases, which may be associated with seizures; allow Day-Night Programming; offer Scheduled Programming; and log low heart rate and prone position events.\n<\/p>\n<p>\n\u201cWe\u2019re proud to offer SenTiva DUO to serve patients who were early adopters of VNS Therapy many years ago,\u201d said Damien McDonald, Chief Executive Officer of LivaNova. \u201cOver time, all VNS Therapy patients must replace their generators as batteries become depleted. Now, our \u2018pioneer patients\u2019 will be able to take advantage of the latest technology with SenTiva DUO and experience the full benefits of VNS Therapy, without the need to replace their dual-pin lead.\u201d\n<\/p>\n<p>\nSenTiva DUO received 510(k) clearance from the U.S. Food and Drug Administration and is currently available in the United States.\n<\/p>\n<p><b>About VNS Therapy for Epilepsy<\/b><\/p>\n<p>\nVNS Therapy is clinically proven safe and effective as an add-on treatment for drug-resistant epilepsy in adults and children as young as 4 years old with partial onset seizures. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy\u2014a condition that affects approximately one in three people with epilepsy. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.livanova.com%2Fepilepsy-vnstherapy%2Fen-us&amp;esheet=53294663&amp;newsitemid=20230131005958&amp;lan=en-US&amp;anchor=VNSTherapy.com&amp;index=1&amp;md5=161bfe2e0658d0cf7807befe81ca5b1c\">VNSTherapy.com<\/a>.\n<\/p>\n<p>\nINTENDED USE\/INDICATIONS \u2013 UNITED STATES\n<\/p>\n<p>\nThe VNS Therapy\u2122 System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. Incidence of adverse events following stimulation (&gt;5%) were voice alteration, increased coughing, hoarseness, shortness of breath, sore throat and nausea. Infection is the most common adverse side effect of the surgical procedure. See important safety information at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.livanova.com%2Fepilepsy-vnstherapy%2Fen-us%2Fsafety-information&amp;esheet=53294663&amp;newsitemid=20230131005958&amp;lan=en-US&amp;anchor=VNSTherapy.com%2Fsafety&amp;index=2&amp;md5=a5eb30d91b54714928674316fc95e413\">VNSTherapy.com\/safety<\/a>.\n<\/p>\n<p><b>About LivaNova<\/b><\/p>\n<p>\nLivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.livanova.com&amp;esheet=53294663&amp;newsitemid=20230131005958&amp;lan=en-US&amp;anchor=www.livanova.com&amp;index=3&amp;md5=da6c9e06591a356d88ddb297e4c402af\">www.livanova.com<\/a>.\n<\/p>\n<p><b>Safe Harbor Statement<\/b><\/p>\n<p>\nThis news release contains \u201cforward-looking statements\u201d concerning the Company\u2019s goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding VNS Therapy, SenTiva DUO and SenTiva. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company\u2019s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230131005958r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/<\/a><\/span><\/p>\n<p><b>LivaNova Investor Relations and Media Contacts<\/b><\/p>\n<p>\n+1 281-895-2382\n<\/p>\n<p><b>Briana Gotlin<br \/>\n<\/b><br \/>Director, Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:InvestorRelations@livanova.com\">InvestorRelations@livanova.com<\/a><\/p>\n<p><b>Deanna Wilke<br \/>\n<\/b><br \/>VP, Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Corporate.Communications@livanova.com\">Corporate.Communications@livanova.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America United States Ireland United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Neurology Cardiology Biotechnology Surgery Health FDA Medical Devices Hospitals<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/555341\/3\/LN-Logo-Main-PANTONE.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/3\/SenTiva_Duo_Updated_B.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">LivaNova&#8217;s SenTiva DUO\u2122, an implantable pulse generator with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. (Photo: Business Wire)<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>LivaNova Launches SenTiva DUO New device expands access to the latest technology for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S. LONDON&#8211;(BUSINESS WIRE)&#8211; LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO\u2122, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva\u2122, which is only available in a single-pin format. Now, with SenTiva DUO, patients considered \u201cthe pioneers of VNS Therapy\u201d who were originally implanted with a dual-pin lead and IPG can receive the benefits of the latest VNS Therapy technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/ &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LivaNova Launches SenTiva DUO&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728245","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LivaNova Launches SenTiva DUO - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LivaNova Launches SenTiva DUO - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LivaNova Launches SenTiva DUO New device expands access to the latest technology for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S. LONDON&#8211;(BUSINESS WIRE)&#8211; LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO\u2122, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva\u2122, which is only available in a single-pin format. Now, with SenTiva DUO, patients considered \u201cthe pioneers of VNS Therapy\u201d who were originally implanted with a dual-pin lead and IPG can receive the benefits of the latest VNS Therapy technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/ &hellip; Continue reading &quot;LivaNova Launches SenTiva DUO&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-02T14:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LivaNova Launches SenTiva DUO\",\"datePublished\":\"2023-02-02T14:10:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/\"},\"wordCount\":817,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005958\\\/en\\\/1701271\\\/4\\\/SenTiva_Duo_Updated_B.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/\",\"name\":\"LivaNova Launches SenTiva DUO - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005958\\\/en\\\/1701271\\\/4\\\/SenTiva_Duo_Updated_B.jpg\",\"datePublished\":\"2023-02-02T14:10:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005958\\\/en\\\/1701271\\\/4\\\/SenTiva_Duo_Updated_B.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005958\\\/en\\\/1701271\\\/4\\\/SenTiva_Duo_Updated_B.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/livanova-launches-sentiva-duo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LivaNova Launches SenTiva DUO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LivaNova Launches SenTiva DUO - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/","og_locale":"en_US","og_type":"article","og_title":"LivaNova Launches SenTiva DUO - Market Newsdesk","og_description":"LivaNova Launches SenTiva DUO New device expands access to the latest technology for legacy VNS Therapy patients with drug-resistant epilepsy in the U.S. LONDON&#8211;(BUSINESS WIRE)&#8211; LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO\u2122, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy\u2122 for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva\u2122, which is only available in a single-pin format. Now, with SenTiva DUO, patients considered \u201cthe pioneers of VNS Therapy\u201d who were originally implanted with a dual-pin lead and IPG can receive the benefits of the latest VNS Therapy technology. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20230131005958\/en\/ &hellip; Continue reading \"LivaNova Launches SenTiva DUO\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-02T14:10:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LivaNova Launches SenTiva DUO","datePublished":"2023-02-02T14:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/"},"wordCount":817,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/","name":"LivaNova Launches SenTiva DUO - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg","datePublished":"2023-02-02T14:10:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230131005958\/en\/1701271\/4\/SenTiva_Duo_Updated_B.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/livanova-launches-sentiva-duo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LivaNova Launches SenTiva DUO"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728245"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728245\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}